leadf
logo-loader
RNS
viewHikma Pharmaceuticals PLC

Hikma Pharmaceutical - AGM Update

RNS Number : 4929I
Hikma Pharmaceuticals Plc
02 April 2020
 

Hikma Pharmaceuticals PLC - AGM Venue

 

 

London, 2 April 2020 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma), following due consideration and given the recent guidance from the Investment Association, GC100 and others relating to the holding of general meetings, is to change the venue for its Annual General Meeting ('AGM').

 

The meeting will now be held at 22 Regent Road, Surbiton KT5 8NL.  As two shareholders reside at this address and the government has forbidden public meetings of more than two people, no additional shareholders will be admitted. The time and date remain unchanged at 10.00 am on Thursday 30 April 2020.  

 

As previously announced, shareholders will still be able to listen remotely and to submit their proxy forms and any questions in advance of the meeting.  Please see 'Remote Attendance', below, for further details. 

 

The Board encourages shareholders to monitor the Company's website and regulatory news services for any updates in relation to the AGM that may need to be provided and encourages shareholders to submit their proxies as early as possible, as the situation continue to change.  Should shareholders have any questions, please contact the Company Secretary at cosec@hikma.uk.com

 

Remote Attendance

 

Shareholders may not attend the meeting in person.  Shareholders may listen to the meeting remotely.  Please be aware that such remote listening is at the discretion of the AGM Chairman and connectivity cannot be guaranteed.  Shareholders listening remotely will not be counted as being present at the meeting and, therefore, will not be able to vote at the meeting and will not have the ability to speak or ask questions.  Shareholders listening remotely are encouraged to do the following in advance of the meeting:

 

1.   Lodge your proxy votes with the registrar (www.hikmashares.com) in accordance with the instructions contained in the Notice of AGM which has separately been made available to shareholders - these will be counted in the votes for the meeting

 

2.   Submit any questions to the Company Secretary (cosec@hikma.uk.com) - these questions will be answered at the meeting in the normal way

 

Telephone

 

1.   Dial the appropriate telephone number from the list below

a.   Jordan: +96265802909

b.   UK: +442038924456

c.   US: +16142414100

d.   Other international numbers available: https://hikma.zoom.us/zoomconference 

 

2.   Enter the meeting ID (577 822 004) followed by #. 

 

3.   There is no participant ID, therefore, press #.

 

4.   You will automatically be placed on mute and will not be able to speak

 

Web-Based Access

 

1.   Open a web browser, ideally Chrome

 

2.   Enter the web address https://hikma.zoom.us/j/577822004  

 

3.   Choose to 'Join with Computer Audio'

 

4.   You will automatically be placed on mute and will not be able to speak

 

Skype Access

 

1.   Open a web browser

 

2.   Enter the web address https://hikma.zoom.us/skype/577822004  

 

3.   Choose to 'Join Zoom Meeting'

 

4.   You will automatically be placed on mute and will not be able to speak

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary                                                                 +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs                                           +44 (0)20 7399 2760

 


About Hikma

 

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURIBMRTMTMMBTM

Quick facts: Hikma Pharmaceuticals PLC

Price: 2653

Market: AIM
Market Cap: £6.11 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE